Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: NeuroInvestment who wrote (14509)	12/6/2004 8:58:45 PM
From: Archie Meeties	Read Replies (1) \| Respond to of 52153

"The role of metabolism in inducing apoptosis was studied further by the investigation of the stable metabolites of clozapine and an analog of clozapine that is refractory to metabolic bioactivation. In accordance with our previous study of clozapine-induced cytotoxicity (Williams et al., 1997), we found that demethylclozapine was less potent than clozapine in inducing apoptosis via the bioactivation-dependent pathway, probably reflecting a lower cellular uptake, because turnover to its nitrenium metabolite was similar to that of clozapine." Mol Pharmacol. 2000 Jul;58(1):207-16. Induction of Metabolism-Dependent and -Independent Neutrophil Apoptosis by Clozapine Dominic P. Williams, Munir Pirmohamed, Dean J. Naisbitt, Jack P. Uetrecht, and Brian K. Park